ACXP
Acurx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.14
+3.64%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.11
From 52W high−83.74%
Volume51091.00
Market cap$6.24M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.11
From 52W high
−83.74%
Volume
51091.00
Market cap
$6.24M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
28.5
MomentumView details →
1D Return
+3.64%
YTD Return
−55.42%
SummaryUpdated Jun 1, 2026
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Staten Island, New York. The company went public in June 2021 and focuses on developing novel antibiotics to treat serious bacterial infections. Acurx's primary focus is advancing its lead drug candidate, ibezapolstat, through clinical trials for treating Clostridium difficile infections, a potentially life-threatening condition that affects hundreds of thousands of patients annually.
Similar companies
Latest newsMore news →
Acurx Pharmaceuticals enrolled the first patient in its Phase 2 PATHFINDER clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection.21d agoAcurx Pharmaceuticals received conditional acceptance from the FDA and trademark allowance from the USPTO for the brand name CIFBEZY for its drug candidate ibezapolstat.64d ago